TLV logotyp

Health Technology Assessment of Optune

TLV has conducted a health technology assessment of Optune. In this health technology assessment, Optune is evaluated in combination with Temozolomide as maintenance therapy in patients with newly-diagnosed glioblastoma. The health technology assessment includes an economic evaluation of Optune and is based on a randomized, multicentre, open-label phase III study. The health technology assessment report presented by TLV provides a basis for decisions made by the county councils.

Optune is based on the tumour-treating fields (TTFields) technology. TTFields are electrical fields that inhibit cell division (mitosis) of proliferating cells. Optune is intended for patients diagnosed with histologically-confirmed glioblastoma.

Glioblastoma is the most common type of malignant brain tumor among adults. TLV assesses this condition as extremely severe. Median progression-free survival from the randomization was 6.7 months for the Optune and Temozolomide group, as compared with four months for the Temozolomide alone group. Median overall survival from randomization was 20.9 months for the Optune and Temozolomide group as compared to 16 months for the Temozolomide alone group. Impairment of important quality of life parameters, such as pain and leg weakness, were statistically significantly delayed for patients using Optune. Even though the follow-up period in the clinical study is extensive, there are uncertainties regarding to how much longer patients live if they have been treated with Optune with Temozolomide versus Temozolomide alone, as well as uncertainty concerning the assessment of quality of life in the clinical study.

In the economic evaluation of Optune, the company's economic model is based on clinical study data that has been extrapolated for the patients’ lifetime horizon using published epidemiological data. Both TLV and the company use a product cost of SEK 189 000 per month. According to the company's calculations, the cost per quality-adjusted life years (QALY) is SEK 1.8 million if Optune has a monthly cost of SEK 189 000. TLV calculates that SEK 2.1 million is a better estimate.

Publicerad 01 mars 2018

Öppettider

Måndag- fredag
09:00 - 16:00.

Växel: 09:00 -16:00.
Registratur:  09:00 -15:00.

 

Kontakt

Telefon växel: 08 - 568 420 50

Fax:
08 568 420 99


E-post: registrator@tlv.se

Besöksadress
Fleminggatan 18
112 26 Stockholm


Postadress
TLV
Box 225 20
104 22 Stockholm

Fakturaadress:
TLV
FE 909
838 74 Frösön


Organisationsnummer:
202 100 - 5364

 

Följ TLV